JPMorgan Chase & Co. set a GBX 5,500 ($75.99) price objective on AstraZeneca (LON:AZN) in a research report released on Thursday, February 8th. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities analysts also recently commented on the company. Goldman Sachs Group restated a sell rating and issued a GBX 3,800 ($52.50) price objective on shares of AstraZeneca in a report on Tuesday, October 17th. Barclays reiterated an overweight rating and issued a GBX 6,300 ($87.04) target price on shares of AstraZeneca in a research note on Monday, December 18th. Credit Suisse Group upgraded AstraZeneca from a neutral rating to an outperform rating and raised their price objective for the company from GBX 4,800 ($66.32) to GBX 5,800 ($80.13) in a research note on Monday, October 16th. Deutsche Bank raised their price objective on AstraZeneca from GBX 5,600 ($77.37) to GBX 5,700 ($78.75) and gave the company a buy rating in a research note on Tuesday, December 5th. Finally, Morgan Stanley set a GBX 4,700 ($64.94) target price on AstraZeneca and gave the stock a neutral rating in a report on Friday, October 20th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of GBX 5,211.65 ($72.00).
AstraZeneca (AZN) opened at GBX 4,696.40 ($64.89) on Thursday. The firm has a market capitalization of $60,920.00 and a PE ratio of 2,746.43. AstraZeneca has a 12-month low of GBX 4,260 ($58.86) and a 12-month high of GBX 5,520 ($76.26).
The business also recently announced a dividend, which will be paid on Monday, March 19th. Investors of record on Thursday, February 15th will be issued a GBX 133.60 ($1.85) dividend. This represents a dividend yield of 2.8%. This is a boost from AstraZeneca’s previous dividend of $68.90. The ex-dividend date of this dividend is Thursday, February 15th.
In other AstraZeneca news, insider Philip A. J. Broadley purchased 415 shares of the stock in a transaction dated Friday, February 2nd. The shares were acquired at an average price of GBX 4,846 ($66.95) per share, for a total transaction of £20,110.90 ($27,785.16).
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/15/astrazeneca-azn-pt-set-at-gbx-5500-by-jpmorgan-chase-co-2.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.